Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Primary results from BEATcc, a randomised phase III trial of first-line atezolizumab combined with a platinum doublet and bevacizumab for metastatic cervical cancer

ESMO Virtual Plenary

Session date: 3 November 2023


VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)

Published: November 3, 2023
DOI: 10.1016/j.annonc.2023.10.694
Download PDF

A. Oaknin, L. Gladieff, J. Martinez-Garcia... L. Randall
Show authors and affiliations


The open-label randomised phase 3 BEATcc academic trial (NCT03556839) evaluated atezo (anti-PD-L1) combined with first-line chemotherapy (CT) + bev for R/M CC, irrespective of PD-L1 status. We report final progression-free survival (PFS) and interim overall survival (OS) results.


Patients (pts) with previously untreated measurable R/M CC not amenable to curative surgery/radiation were randomised 1:1 to standard therapy (cisplatin 50 mg/m2 or carboplatin AUC5 + paclitaxel 175 mg/m2 + bev 15 mg/kg) ± atezo 1200 mg d1 q3w. Cycles were repeated until disease progression or unacceptable toxicity. Stratification factors were prior concomitant chemoradiation (yes vs no), histology (squamous cell carcinoma vs adenocarcinoma) and platinum agent (cisplatin vs carboplatin). Dual primary endpoints were investigator-assessed PFS per RECIST v1.1 and OS. Secondary endpoints included objective response rate (ORR), duration of response (DoR), time to first subsequent therapy (TFST), PFS2, and safety.


Between Oct 2018 and Aug 2021, 410 pts were randomised. At the data cut-off (median follow-up 32.9 mo), median treatment duration was 8.5 vs 12.7 mo in the control vs atezo arms, respectively; treatment was ongoing in 7% vs 23%, respectively. Both PFS and OS were statistically significantly improved with the addition of atezo to CT + bev (Table). Secondary endpoints and subgroup analyses showed consistent results. Grade ≥3 adverse events (any cause) occurred in 75% vs 79% of the control and atezo arms, respectively. Safety profiles were as expected with bev + platinum-based CT. Grade 1/2 diarrhoea, arthralgia, pyrexia and rash were increased with atezo.


CT + bev (n=204)

Atezo + CT + bev (n=206)


Events, n (%)

166 (81)

138 (67)


0.62 (0.49–0.78); p<0.0001

Median, mo

10.4 (9.7–11.7)

13.7 (12.3–16.6)

2-year rate, %

19 (14–25)

36 (29–43)


Events, n (%)

129 (63)

105 (51)


0.68 (0.52–0.88); p=0.0046*

Median, mo

22.8 (20.3–28.0)

32.1 (25.3–36.8)

2-year rate, %

49 (41–56)

61 (53–67)


Median, mo

13.2 (12.0–14.3)

19.0 (16.4–24.0)


0.60 (0.47–0.76)


Median, mo

20.3 (17.8–22.3)

25.8 (22.1–32.1)


0.61 (0.48–0.79)

ORR per RECIST v1.1, %

72 (66–78)

84 (79–89)





Median, mo

8.6 (8.0–10.6)

13.6 (10.6–21.3)


0.60 (0.46–0.78)

Brackets show 95% CIs unless otherwise stated HR = hazard ratio *Statistically significant at interim analysis


Adding atezo to first-line CT + bev for R/M CC significantly improved all efficacy outcomes. Median OS with atezo + CT + bev exceeded 2.5 years.

Clinical trial identification

NCT03556839; EudraCT 2018-000367-83; ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030/BEATcc.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.